John Oyler Sells 58,590 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC) CEO John Oyler sold 58,590 shares of Beigene stock in a transaction on Friday, March 7th. The stock was sold at an average price of $249.13, for a total transaction of $14,596,526.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

John Oyler also recently made the following trade(s):

• On Monday, March 3rd, John Oyler sold 101,000 shares of Beigene stock. The stock was sold at an average price of $244.30, for a total transaction of $24,674,300.00.

Beigene Stock Performance

Beigene stock opened at $247.07 on Friday. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The stock has a market cap of $24.18 billion, a P/E ratio of -29.98, a PEG ratio of 7.73 and a beta of 0.65. Beigene, Ltd. has a 12-month low of $126.97 and a 12-month high of $287.88.

Beigene (NASDAQ:ONC) last released its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.55). The firm had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. On average, equities research analysts expect that Beigene, Ltd. will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ONC shares. Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and raised their target price for the stock from $207.00 to $320.00 in a research note on Monday, March 3rd. Macquarie lifted their price objective on Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.